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Hypoxia results from an imbalance between oxygen de-livery and demand (1). Tumor hypoxia is an impor-
tant negative prognostic factor in human cancers (2–4) 
and predicts treatment failure to both radiation therapy 
(5) and numerous chemotherapeutic agents (6). Interest 
in modifying or exploiting hypoxia has driven attempts 
to develop new treatments for use in combination with 
radiation therapy and chemotherapy (7). Effective devel-
opment and delivery of these treatments requires imaging 
biomarkers that can rapidly identify and accurately assess 
the extent and spatial distribution of tumor hypoxia (8).
MRI techniques are being investigated for delivering 
translational biomarkers of hypoxia (9). Historically, 
interest has focused on intrinsic susceptibility imaging, 
which quantifies native values of effective transverse relax-
ation rate (R2*) and the change in R2* (∆R2*) induced 
by respiratory challenge with hyperoxic gas (10,11). 
However, there has been recent interest in quantifying 
the change in  the longitudinal relaxation rate (R1) after 
inhalation of 100% oxygen (12). In this latter technique, 
referred to as oxygen-enhanced (OE) MRI, paramagnetic 
oxygen molecules dissolved in blood plasma, interstitial 
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Purpose: To cross-validate T1-weighted oxygen-enhanced (OE) MRI measurements of tumor hypoxia with intrinsic susceptibility 
MRI measurements and to demonstrate the feasibility of translation of the technique for patients.
Materials and Methods: Preclinical studies in nine 786–0-R renal cell carcinoma (RCC) xenografts and prospective clinical studies in 
eight patients with RCC were performed. Longitudinal relaxation rate changes (∆R1) after 100% oxygen inhalation were quanti-
fied, reflecting the paramagnetic effect on tissue protons because of the presence of molecular oxygen. Native transverse relaxation 
rate (R2*) and oxygen-induced R2* change (∆R2*) were measured, reflecting presence of deoxygenated hemoglobin molecules. 
Median and voxel-wise values of ∆R1 were compared with values of R2* and ∆R2*. Tumor regions with dynamic contrast agent–
enhanced MRI perfusion, refractory to signal change at OE MRI (referred to as perfused Oxy-R), were distinguished from perfused 
oxygen-enhancing (perfused Oxy-E) and nonperfused regions. R2* and ∆R2* values in each tumor subregion were compared by 
using one-way analysis of variance.
Results: Tumor-wise and voxel-wise ∆R1 and ∆R2* comparisons did not show correlative relationships. In xenografts, parcellation 
analysis revealed that perfused Oxy-R regions had faster native R2* (102.4 sec–1 vs 81.7 sec–1) and greater negative ∆R2* (222.9 
sec–1 vs 25.4 sec–1), compared with perfused Oxy-E and nonperfused subregions (all P , .001), respectively. Similar findings were 
present in human tumors (P , .001). Further, perfused Oxy-R helped identify tumor hypoxia, measured at pathologic analysis, in 
both xenografts (P = .002) and human tumors (P = .003).
Conclusion: Intrinsic susceptibility biomarkers provide cross validation of the OE MRI biomarker perfused Oxy-R. Consistent rela-
tionship to pathologic analyses was found in xenografts and human tumors, demonstrating biomarker translation.
Published under a CC BY 4.0 license.
Online supplemental material is available for this article.
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tissue fluid, or intracellular water can induce changes in R1 
(∆R1) (13). Numerous studies (14–18) have reported an in-
crease in R1 in well-oxygenated tissues after challenge with 
hyperoxic gas. In hypoxic tissue, the inhaled oxygen molecules 
bind preferentially to deoxygenated hemoglobin molecules, 
converting the paramagnetic deoxyhemoglobin to diamagnetic 
oxyhemoglobin. Hence, in hypoxic tumor subregions, there is 
no measurable positive ∆R1 (19).
We recently showed (20,21) in multiple preclinical xeno-
graft models that tumor voxels with demonstrable perfusion 
but absent ∆R1 (oxygen refractory on R1 mapping referred to 
as perfused Oxy-R) represent a noninva-
sive signature of hypoxia at MRI. This 
finding suggests that OE MRI may have 
a translational benefit compared with 
R2*-based methods. Previous studies re-
ported complex and nonlinear relation-
ships between ∆R1 and ∆R2* in xeno-
grafts (22–26) or patient tumors (27) 
(Fig 1). However, to our knowledge, no 
cross-validation has been performed to 
evaluate whether perfused Oxy-R– and 
R2*-based biomarkers measure the same 
underlying tumor biology.
In our study, we hypothesized that 
tumor subregions identified as perfused 
Oxy-R would have faster native R2* and 
greater negative ∆R2*. We investigated 
this spatial relationship by using a renal 
cell carcinoma (RCC) xenograft model 
in which perfused Oxy-R was previously 
validated with pathologic measurement 
of hypoxia (21). We then performed a 
clinical study in patients with RCC tu-
mors. The purpose was to cross-validate 
a T1-weighted OE MRI measurement of 
tumor hypoxia with T2*-weighted intrin-
sic susceptibility MRI measurements and 
to demonstrate the feasibility of transla-
tion of the technique into patients.
Abbreviations
∆R1 = change in R1, ∆R2* = change in R2*, DCE = dynamic contrast 
enhanced, OE = oxygen enhanced, RCC = renal cell carcinoma
Summary
Intrinsic susceptibility imaging and immunohistochemistry analysis 
were used to validate a combined end point of oxygen enhancement 
plus MR-derived perfusion as a biomarker of tumor hypoxia in mouse 
and patient studies.
Implications for Patient Care
 n Oxygen-enhanced MRI is a feasible method to identify and map 
tumor hypoxia in patients.
 n Oxygen-enhanced MRI identifies spatial heterogeneity in tumor 
hypoxia, which may identify response to therapy and aid personal-
ized radiation therapy treatment planning.
Figure 1: Schematic representation of postulated relationship between oxygen-induced 
change in R2* (∆R2*) and change in R1 (∆R1) MRI biomarkers of tumor hypoxia. It is postulated 
that change in R1 measures increase in dissolved oxygen in tissue. The theoretical relationships 
between voxels with different perfusion and oxygenation status are considered, along with 
physics confounds, such as inflow effects. Hypothetical distributions of voxels are indicated for 
normoxic (yellow), hypoxic (blue), and nonperfused (gray) tumor subregions.
Materials and Methods
AstraZeneca provided a salary to one author (K.F.H.). Two re-
searchers provided consultancy to Bioxydyn (G.J.M.P. and 
J.C.W.). Authors who are not employees of or consultants for As-
traZeneca and Bioxydyn had full control of inclusion of any data.
Preclinical MR Data Acquisition
Experiments were performed in compliance with licenses is-
sued under the UK Animals (Scientific Procedures) Act 1986, 
following local ethical review, and the United Kingdom Na-
tional Cancer Research Institute guidelines for animal welfare 
in cancer research (28). The subcutaneous 786–0 RCC xeno-
graft model (29), detailed MRI analysis, and pathologic analy-
sis are described in Appendix E1 (online).
When the tumors were approximately 400 mm3, tumors 
were evaluated on a 7.0-T horizontal bore MRI system (Bruker, 
Ettlingen, Germany). Details of the anesthesia procedure are in 
Appendix E1 (online). After localization and shimming over 
the tumor, one axial imaging section was collected for all func-
tional sequences. One R2* measurement was performed be-
fore and after the OE MRI sequence. Finally, dynamic contrast 
agent–enhanced (DCE) MRI (30) was performed while the 
mice inhaled 100% oxygen to define tumor perfusion. Func-
tional imaging sequences (Table 1)were as follows:
1. Intrinsic susceptibility imaging: multiple gradient-echo 
images to derive R2*.
2. OE MRI: inversion recovery true-fast imaging with 
steady-state precession  images to derive R1 at baseline and 
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Table 1: Imaging Sequence Details
Parameter Preclinical Study Clinical Study
Geometry for all functional sequences
 Field of view (mm) 30 3 30 375 3 375
 Matrix 128 3 128 128 3 128
 In plane resolution (mm) 0.23 2.93
 Section thickness (mm) 1 7
T2*-weighted intrinsic susceptibility MRI
 Sequence type Multiple gradient echo Multiple fast field gradient echo
 Repetition time (msec) 200 80
 Echo time (msec) 6.2–28.2* 4.6–29.6†
 No. of signal averages 8 4
 Flip angle (degrees) 45 41
T1-weighted oxygen-enhanced MRI
 Sequence type Inversion recovery Inversion recovery
 Repetition time (msec) 2.4; scan, 10 000 10 000
 Echo time (msec) 1.2 3.1
 Inversion time (msec) 106.2 followed by 47 inversion times  
38.8-msec apart
50, 200, 500, 1000, 2000, 5000, 1400 
for dynamic
 No. of signal averages 8 1
 Temporal resolution (sec) 160 30
 Flip angle (degrees) 60 45
T1-weighted dynamic contrast-enhanced MRI
 Sequence type Inversion recovery T1-weighted fast field echo
 Repetition time (msec) 2.4 2.4
 Echo time (msec) 1.2 0.8
 Inversion time (msec) 108 followed by 7 inversion time,  
155-msec apart
…
 No. of signal averages 2 5
 Flip angle (degrees) 60 2, 10, 20 for native T1 measurement; 
20 for dynamic
 Temporal resolution (sec) 20 2.3
* 3.1-msec echo spacing 
† 5-msec echo spacing
dynamically throughout the gas challenge. The dynamic series 
was performed for 10 minutes 40 seconds. This sequence is 
relatively insensitive to inflow effects.
3. DCE MRI: R1 was measured by using a modified true-
fast imaging with steady-state precession sequence. After five 
baseline measurements, 0.1 mmol/kg bolus of gadopentetate 
dimeglumine (Magnevist; Bayer, Leverkusen, Germany) was 
injected intravenously at 2 mL/min by using a power injector. 
The dynamic series was acquired for 10 minutes 40 seconds.
Clinical Study MRI Data Acquisition
Studies were performed after research ethics approval and insti-
tutional board review. Oxygen administration was not regarded 
as an investigational medicinal product study after consulta-
tion with the UK Medicines and Health Care Products Regula-
tory Agency. All patients gave fully informed written consent.
Patients with surgically resectable RCC (stage T1–T3, N0, 
M0) were recruited before nephrectomy. Subsequent immuno-
histochemical detection of the hypoxia-regulated gene glucose 
transporter 1 (GLUT1) provided an indirect assessment of tu-
mor hypoxia (31).
Gas delivery (medical air or 100% oxygen) was at 15 L/
min through a nonrebreathing mask (Adult EcoLite High 
Concentration Oxygen mask; InterSurgical, Berkshire, Eng-
land). Oxygen concentration in the mask was monitored con-
tinuously (ML206 Gas Analyzer and Powerlab 8/35; ADIn-
struments, Oxford, England) and analyzed (LabChart version 
7.3.4; ADInstruments).
Data were acquired by using a 1.5-T horizontal bore 
magnet (Philips Healthcare, Eindhoven, the Netherlands). 
Patients were imaged in the supine position with the scan-
ner body resonator (Q body coil; Philips Healthcare) used 
in transmit and receive mode. After localization, one oblique 
coronal section was acquired that matched the coronal plane 
of the tumor-bearing kidney. Single R2* measurements were 
collected before and after the OE MRI sequence. Finally, 
DCE MRI was performed. Functional imaging sequences 
(summarized in Table 1) were as follows:
1. Intrinsic susceptibility imaging: multiple gradient-echo im-
ages to calculate R2*.
2. OE MRI: Inversion recovery half-Fourier rapid acquisi-
tion with relaxation enhancement images to calculate R1 at 
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voxels; hypoxic, composed of perfused Oxy-R voxels; and 
nonperfused voxels (Fig 2).
Statistical Analysis
For both preclinical and clinical studies, median values of 
the MRI biomarkers (native R2*, oxygen-induced ∆R2*, 
and oxygen-induced ∆R1) and voxel-wise values were com-
pared by using Spearman r. The relationship of the voxel-
wise R2* and ∆R2* to perfused Oxy-R voxels, perfused 
Oxy-E voxels, and nonperfused voxels was evaluated by 
one-way analysis of variance.
The relationship of tissue pathology to MRI biomarkers 
(native R2*, oxygen-induced ∆R2*, oxygen-induced ∆R1, 
and perfused Oxy-R) in the 786–0-R xenografts was ana-
lyzed by using Spearman r. Clinical tumors were designated 
as either low or high in hypoxic fraction by semi-quanti-
tative pathology, and the values of perfused Oxy-R were 
compared between these two groups by using the Student 
t test. In all cases, P values less than .05 were considered to 
indicate statistical significance following Bonferroni correc-
tion when multiple comparisons were tested.
Results
R1 Biomarkers But Not R2* Biomarkers Relate to 
Hypoxia in 786–0-R Xenographs
The relationships of MRI biomarkers of hypoxia and tissue 
pathologic assessment were determined in the 786–0-R xe-
nografts. Median values of native R2* and oxygen-induced 
∆R2* taken across the entire image did not correlate with 
the hypoxic fraction measured at pimonidazole adduct for-
mation (Figs 3a, 3b). Hypoxic fraction was related to me-
dian values of oxygen-induced ∆R1 (r, 20.783; P = .013; 
Fig 3c) and the perfused Oxy-R fraction (r, 0.902; P = .002; 
Fig 3d).
baseline and dynamically throughout the gas challenge. Dy-
namic images were used to quantify the temporal onset of R1 
changes induced by switching between air and 100% oxygen 
(switch performed after nine baseline measurements).
3. DCE MRI: Native R1 was measured by using a vari-
able flip angle spoiled gradient-echo sequence. Time varying 
R1 was determined by relating the time varying signal change 
to the native R1. After 14 baseline measurements, 0.1 mmol/
kg bolus of gadoterate meglumine (Dotarem; Guerbet, Paris, 
France) was injected intravenously at 3 mL/min by using a 
power injector (Medrad Spectris MR; Bayer, Leverkusen, Ger-
many), followed by a 20-mL saline flush.
MRI Data Analysis
Regions of interest were drawn for tumors on the T2-
weighted images by experienced operators (Y.J., with 13 
years of preclinical experience, and Y.W., with 16 years of 
clinical experience) and transferred to the intrinsic sus-
ceptibility, OE MRI, and DCE MRI data for each tumor. 
Voxel-wise values of native R2*, oxygen-induced ∆R2*, and 
oxygen-induced ∆R1 were calculated for all parameters by 
using in-house software from which median values were 
derived.
For intrinsic susceptibility MRI, the voxel-wise native 
R2* was calculated by using the air-only data. Next, the 
∆R2* was calculated as ∆R2* = R2* (O2) 2 R2* (air), where 
O2 is oxygen. At OE MRI, the voxel-wise ∆R1 was calcu-
lated as ∆R1 = R1 (O2) 2 R1 (air). At DCE MRI, voxels 
were classified as perfused or nonperfused (32).
For combined OE and DCE MRI analysis, voxels were 
classified as enhancing (hereafter, referred to as Oxy-E) or 
refractory (hereafter, referred to as Oxy-R) to oxygen chal-
lenge and then further subclassified as perfused or nonper-
fused by using DCE MRI data. From this, three subregions 
were defined: normoxic, composed of perfused Oxy-E 
Figure 2: Schematic representation 
of analysis method used to define 
tumor subregions. A, For each preclini-
cal and clinical tumor, a T2-weighted 
(T2w) anatomic image is used to define 
a region of interest (tumor; arrow), 
then oxygen-enhanced (OE) MR im-
ages and dynamic contrast-enhanced 
(DCE) MR images are analyzed to 
generate maps of change in longitu-
dinal relaxation rate (∆R1) and the 
initial area under the gadolinium up-
take curve from 0 to 60 seconds after 
injection of Gd-DTPA (IAUC60 ), respec-
tively. B, The ∆R1 and IAUC60 data 
were binarized to produce binary 
enhancement maps, and then, C, com-
bined to generate a map with three 
categories of voxels: perfused and 
OE, perfused but oxygen-refractory, 
and nonperfused.
Little et al
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Figure 3: Graphs show the correlations between hypoxic fraction (expressed as a percentage and calculated from pimonidazole adduct forma-
tion immunohistochemistry images) and MRI biomarkers in 786–0-R tumors propagated in 8-week-old female C.B17-scid mice. Hypoxia did not 
correlate with (a) native R2* (R2*) or (b) oxygen-induced change in R2* (∆R2*), but it did correlate with (c) oxygen-induced change in R1 (∆R1) 
and (d) percentage of tumor perfused Oxy-R (nine mice for a–c and eight mice for d).
Subregional Analysis Reveals the R2* and R1 
Biomarker Relationship in 786–0-R Xenographs
The relationship between R2* and R1 biomarkers was compared. 
Initially, tumor-wise and voxel-wise analyses were investigated by 
following existing literature. Next, we used the combined OE and 
DCE MRI analysis to define the three subregions perfused Oxy-E 
tumor, perfused Oxy-R tumor, and nonperfused tumor.
Tumor-wise analysis.—Median values of native R2* and oxy-
gen-induced ∆R2* were compared with median values of ∆R1 
for each tumor. No significant correlations were observed.
Voxel-wise analysis.—Native R2* and ∆R1 did not have a 
significant relationship. In distinction, there was a highly 
significant but weak correlation between ∆R2* and ∆R1 (r, 
0.230; P , .001; Fig E1 [online]). Voxels with greater nega-
tive gas-induced ∆R2* showed a smaller positive ∆R1, con-
sistent with both being biomarkers of hypoxia. However, the 
relationship between ∆R2* and ∆R1 appeared complex and 
was not explained simply by the bimodal relationship pre-
dicted by the open L-shaped curve (24,27) (Fig 1).
Parcellation analysis.—We defined subregional analysis on 
the basis of the hypoxia biomarker perfused Oxy-R. This 
approach was chosen because we had previously validated 
Oxy-R as a hypoxia biomarker in this xenograft model (21). 
Three subregions were defined on the basis of combined OE 
MRI and DCE MRI signals (Fig 1). Native R2* and oxygen-
induced ∆R2* were compared for each of these subregions. 
In all, 5815 voxels were included and analyzed, of which 
488 (8.4%) were nonperfused; 4547 (78.2%) were defined 
as perfused Oxy-E, suggestive of a normoxic profile; and 780 
(13.4%) were defined as perfused Oxy-R, suggestive of a hy-
poxic profile. Perfused Oxy-R voxels had faster native R2* (P 
, .001; Fig 4a) and greater negative hyperoxia-induced ∆R2* 
(P , .001; Fig 4b) than the perfused Oxy-E and nonperfused 
voxels. Example tumor parametric maps are shown with cor-
responding pathologic validation across the range of hypoxia 
measured (Fig 5).
Technique Translation to Clinical Data
To test clinical translation, we recruited seven patients with 
clear cell RCC at radiologic assessment that was confirmed 
at subsequent histopathologic analysis (Table 2). The com-
bined OE MRI and DCE MRI analysis requires reliable defi-
nition of voxels that are refractory to oxygen challenge. Data 
from the ML206 gas analyzer in all seven patients showed 
statistically significant increase in oxygen concentration to 
greater than 90% during gas challenge (sample trace in Fig 
E2 [online]).
As an additional quality control step, we evaluated the 
∆R1 in the renal cortex to act as a positive control for oxy-
gen delivery because positive ∆R1 has been consistently re-
ported in multiple OE MRI studies (15–17) of the kidney. 
We evaluated renal cortex regions of interest for evidence 
of oxygen enhancement (Fig E3a [online]) and generated 
combined OE MRI and DCE MRI maps for these regions 
(Fig E3b [online]). These analyses showed that whereas all 
patients received high concentration oxygen, one patient 
failed to inhale the gas sufficiently to generate signal change 
Figure 4: Box-and-whisker plots show relationship of voxel values of 
(a) native R2* (R2*) and (b) oxygen-induced change in R2* (∆R2*) to 
tumor subregions categorized by perfused Oxy-E, nonperfused (NP), 
and perfused Oxy-R in 786–0-R tumors propagated in 8-week-old female 
C.B17-scid mice (n = 8). Data are medians and interquartile range.
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6.6%, 1.8%, and 0.6%) had GLUT1 hypoxia scores of 4.2, 
2, 10.3, and 1.7, respectively, whereas the two tumors with 
high MRI hypoxic fraction (31.7% and 28.8%) had GLUT1 
hypoxia scores of 19.5 and 41.7, respectively (Fig 7). Therefore, 
OE MRI helped to categorize the six patient tumors into two 
groups and helped to detect significant separation in GLUT1 
hypoxia score (P = .003).
Discussion
There is a need to develop noninvasive biomarkers of tumor 
hypoxia. Potential applications include identifying patients 
who would benefit from modifying hypoxia before radiation 
therapy (7), identifying persistence of hypoxia during conven-
tional treatment regimens (33), mapping targets for radiation 
boost or adaptive therapy (34), and monitoring changes in tu-
mors treated with hypoxia-modifying therapies (7).
Whereas biomarkers have enormous potential in cancer, most 
failed to translate into practice-changing tools (35). Consequently, 
there is growing recognition that imaging biomarkers in develop-
ment must undergo rigorous technical and biologic validation be-
fore they can be qualified as clinically useful (36).
Proton MRI methods are attractive because they are read-
ily available and provide a cost-effective source of spatially lo-
calized information for various structural, functional, and mo-
lecular biomarkers of cancer (12). In this study, we sought to 
in the renal cortex (only 3.0% 
of voxels were oxygen enhanc-
ing). All other patients with 
renal cortex in the field of 
view had significant positive 
∆R1 in the renal cortex with 
between 83.7% and 100% 
(mean, 95.4%) of OE voxels 
(Table 2). Patient 7 had no 
normal kidney included in 
the field of view, but equiva-
lent analysis of the spleen 
confirmed successful oxygen 
enhancement.
Consistent Relationship 
between R2* and R1 
Biomarkers Found in 
Human RCC Tumors 
The analyses developed in the 
786–0-R xenografts were ap-
plied to the patient data. Patient 
6 tumor data were excluded be-
cause this patient failed quality 
control checks on the basis of 
renal cortex analysis. This tumor 
did not show significant oxygen 
enhancement in 84.3% of its 
voxels (Fig E4 [online]), which 
is consistent with a failure in gas 
delivery.
Tumor-wise analysis.—Median values of native R2* and gas-
induced ∆R2* were compared with median values of ∆R1 for 
each tumor (n = 6). No significant correlations were observed.
Voxel-wise analysis.—Native R2* and ∆R1 did not have a sig-
nificant relationship. However, there was a highly significant 
but weak correlation between ∆R2* and ∆R1 (r, 0.035; P , 
.001). Voxels with greater negative gas-induced ∆R2* showed a 
smaller change in R1 (Fig E5 [online]).
Parcellation analysis.—Native R2* and gas-induced ∆R2* 
were compared for each of three subregions, defined by their 
combined signals at OE MRI and DCE MRI. In total, 4112 
voxels were measured, of which 436 (10.6%) were nonper-
fused, 2887 (70.2%) were defined as perfused Oxy-E sugges-
tive of a normoxic profile, and 789 (19.2%) were defined as 
perfused Oxy-R suggestive of a hypoxic profile. Statistically 
significant differences were observed between the perfused 
Oxy-R voxels (predicted to be hypoxic) and both the per-
fused Oxy-E and the nonperfused voxels, with faster native 
R2* and a greater negative gas-induced ∆R2* in the perfused 
Oxy-R voxels (both P , .001) (Figs 6a, 6b).
In an exploratory analysis, we scored tumor hypoxia by 
GLUT1 staining. Although the study was not powered for-
mally, the four tumors with MRI low hypoxic fraction (9.1%, 
Figure 5: Representative parametric maps of change in R2* (∆R2*), change in R1 (∆R1), and com-
bined oxygen-enhanced MRI and dynamic contrast-enhanced MRI (quantifying perfused Oxy-E, perfused 
Oxy-R, and nonperfused tumor) are shown for three 786–0-R tumors propagated in 8-week-old female 
C.B17-scid mice, showing least, middle and greatest hypoxic fractions (HF) measured by pimonidazole 
adduct formation.
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Table 2: Patient Demographics, Stage, and Biomarker Values
Parameter Age (y) Sex
TNM  
Stage
Renal Cortex Tumor
∆R1 (sec21)
Perfused  
Oxy-E (%)
R2* air  
(sec21)
∆R2*  
(sec21)
∆R1  
(sec21)
Perfused  
Oxy-E (%)
Perfused  
Oxy-R (%)
Not  
Perfused (%)
Patient No.
 1 68 F T2a 0.0416 100 15.3 3.82 0.0495 97.0 1.8 1.2
 2 63 F T2a 0.0555 100 26.4 21.80 0.0350 69.3 6.6 24.1
 3 46 F T3a 0.0467 97.4 18.8 0.76 0.0232 66.4 9.1 24.5
 4 78 F T3a 0.1070 83.7 18.7 22.77 0.0245 68.1 31.7 0.2
 5 52 F T1b 0.0265 100 9.0 2.72 0.0208 99.4 0.6 0
 6 44 F T3a 0.0021 3.0 14.5 …* …* …* …* …*
 7 54 M T3b NA NA 16.3 2.26 0.0177 62.9 28.8 8.3
Note.—∆R1 = change in R1, ∆R2* = change in R2*, F = female, M = male, NA = not available.
* Failed quality control for oxygen-enhanced MRI ∆R1 and ∆R2*.
cross-validate oxygen-induced changes in R1, particularly the 
biomarker perfused Oxy-R, with the MRI biomarkers native 
R2* and oxygen-induced ∆R2*. This step is important because 
these different putative approaches to mapping hypoxia rely on 
different mechanisms and if measurements made by using these 
different approaches are mutually consistent, their validity is 
supported according to the Hill principle of coherence (37).
Initially, we compared four biomarkers of hypoxia mea-
sured tumor-wise (native R2*, oxygen-induced ∆R2*, oxygen-
induced ∆R1, and perfused Oxy-R). The two R1-based bio-
markers had significant relation to the pimonidazole-positive 
fraction in the well-vascularized but hypoxic 786–0-R RCC xe-
nograft model, whereas native R2* and ∆R2* did not. At first, 
this supports the hypothesis that R1-based imaging biomarkers 
measure hypoxia, but it refutes the hypothesis that R2*- and 
R1-based imaging biomarkers identified the same hypoxic 
tumor subregions.
Next, we compared three biomarkers of tumor hypoxia with 
voxel-wise measurement (native R2*, oxygen-induced ∆R2*, ox-
ygen-induced ∆R1). The relationship observed between oxygen-
induced ∆R2* and oxygen-induced ∆R1 was weak and was not 
described fully by the open L-shaped model predicted by the 
literature (24,27). No relationship was observed between native 
R2* and oxygen-induced ∆R1.
Recognition that tumors are biologically heterogeneous 
suggests a need for an alternative investigative approach. We 
used OE MRI and DCE MRI to derive the biomarker perfused 
Oxy-R, which provides a hypoxic signature in tumor voxels 
(21). We then observed that the perfused Oxy-R tumor sub-
regions had faster native R2* and greater negative ∆R2* after 
oxygen inhalation, as hypothesized, in both mouse xenograft 
tumors and in human RCCs.
This study emphasizes the substantial limitation of the use 
of summary value biomarkers to quantify tumor pathophysi-
ologic features, such as hypoxia, that exhibit pronounced spa-
tial variation (38). The data explain why R2*-based biomarkers 
may be insensitive indicators of hypoxia for some tumors. In 
this scenario, significant volumes of normoxic tissue and non-
perfused tissue (collectively accounting for the vast majority 
of tumor tissue in most cancers) will mask the ability of na-
tive R2* and oxygen-induced ∆R2* to detect hypoxia. Indeed, 
over the last 2 decades, several studies (39–41) reported that 
hypoxic tumor tissue had faster native R2* and a greater nega-
tive ∆R2* after challenge with hyperoxic gas, whereas contrary 
findings (42) were reported elsewhere.
This study highlights the benefits of performing parallel 
preclinical and clinical experiments when evaluating transla-
tional potential of biomarkers, as recommended in the Cancer 
Research UK and European Organization for Research and 
Treatment of Cancer imaging biomarker roadmap (36). Pre-
clinical studies allow rapid and early biologic validation, but 
have differences in data acquisition and analysis that could 
limit the ability of preclinical data to address clinical questions; 
(for example, the field dependence of R2* imaging results in a 
22-fold higher effect at 7.0-T compared with 1.5-T). Despite 
this potential confound, the relationships between R2* and R1 
Figure 6: Box-and-whisker plots show relationship of voxel values of 
(a) native R2* (R2*) and (b) oxygen-induced change in R2* (∆R2*) to 
tumor subregions categorized by perfused Oxy-E, nonperfused Oxy-R, 
and perfused Oxy-R in patients with renal cell carcinoma (n = 6). Data 
are medians and interquartile range.
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biomarkers were equivalent in 
mice and humans: Voxels iden-
tified as having a hypoxic signa-
ture at combined OE MRI and 
DCE MRI (perfused Oxy-R 
voxels) had significantly faster 
native R2* and significantly 
greater oxygen-induced ∆R2* 
compared with voxels in tu-
mor subregions with differing 
pathophysiology.
Further, the relative frac-
tion of normoxic, hypoxic, and 
nonperfused tumor, defined 
by combined OE MRI and 
DCE MRI, was equivalent in 
mice and humans, indicating 
that the 786–0-R tumors were 
an appropriate model of het-
erogeneous hypoxia in clinical 
RCC tumors. Finally, explor-
atory analysis showed that two 
tumors with approximately 30% hypoxia measured by MRI 
had significantly higher GLUT1 expression than the tumors 
with less than 10% hypoxia measured by MRI, providing evi-
dence of equivalent imaging-pathology relationships in mice 
and human tumors.
Some study limitations should be recognized. First, al-
though the findings of a xenograft study have been replicated 
in humans, the clinical sample size was small. Second, the 
one-way analysis of variance for voxel-level analysis does con-
sider the clustering of voxels within the tumor. Third, voxel-
wise data were pooled to perform the analyses on a cohort-
level basis. Finally, whereas many results at the whole-tumor 
level were nonsignificant, this must be interpreted in light of 
the small sample sizes and consequent limited power.
In summary, these data use intrinsic susceptibility im-
aging and immunohistochemistry analysis to cross validate 
perfused Oxy-R as a regional biomarker of tumor hypoxia 
in mice and humans, providing strong rationale for further 
clinical translation of the biomarker. Further studies are re-
quired to test if the same relationships are observed between 
imaging and pathologic analysis and R1-based imaging and 
R2*-based imaging biomarkers in other tumor types, and 
to evaluate the value of perfused Oxy-R as a biomarker of 
prognosis, prediction of treatment response, and detection of 
response to therapy.
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